

REMARKS

In the Office Action of March 19, 2004, claims 11-13 were rejected under 102(a) in view of Yang et al., and claims 15-17 were objected to as depending on a rejected claim.

In response to the rejection of claims 11-13, we enclose the Declaration Under 37 C.F.R. 1.131 of Theodore E. Spielberg affirming that he made the invention defined by these claims prior to January 1, 1994, i.e., prior to the asserted date of the Yang reference.

In response to the objection to claims 15-17, we have amended claim 17 to remove reference to a non-elected claim (claim 1). In light of the attached Declaration, claims 11-13 should now be allowable, and thus claims 15-17 as well.

Please charge any additional fee occasioned by this paper to our Deposit Account No. 03-1237.

Respectfully submitted,



Martin J. O'Donnell
Reg. No. 24,204
CESARI AND MCKENNA, LLP
88 Black Falcon Avenue
Boston, MA 02210-2414
(617) 951-2500

**Claims 11-13DECLARATION UNDER 37 C.F.R. §1.131 OF THEODORE E.
SPIELBERG**

Theodore E. Spielberg, on the basis of personal knowledge, declares as follows:

1. I am the inventor of the subject matter of the above patent application.

2. I am advised that claims 11-13 of the above application have been rejected on the basis of an article "Comparative studies of in vitro and in vivo function of three different bioartificial pancreases made of agarose hydrogel" by Yang et al., Biomaterials 1994, vol. 15, No. 2, January 1994.

As set forth in detail herein, I conceived of the subject matter of these claims within the United States prior to January 1, 1994 and was diligent in reducing it to practice in the United States since the time of conception by filing an application thereon.

3. In particular, the attached "Exhibit A" is a true copy of a portion of notes that I made in connection with documenting the invention. These notes are in my own handwriting, and were made prior to January 1, 1994. A transcription of a portion of the notes specifically discussing the endocrine cell microdisk as defined by claims 11-13, among others, is attached as Exhibit B.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment or both under 18 U.S. Code §1001 and that any

05/31/2005 14:59 FAX

003

such willful false statement may jeopardize the validity of the application or any patent

issued thereon.

May 31, 2005
Date

Theodore E. Spielberg
Theodore E. Spielberg, M.D.

Exhibit A



Brief Description of The Invention:

Instead of the spherical shape of current microcapsules the ~~endocrine cell~~ ^{microcapsules} containing ~~are~~ ^{generally} flattened on two sides creating a coin or pill shape ^{or microdiscs}. This effectively ~~increases~~ ^{increases} the surface/volume ratio of the devices and increasing ~~their~~ ^{the} diffusional capacity ~~per unit~~ ^{per unit} of time. Moreover, when transplanted in a body cavity with large surfaces (vascular membranes) such as the peritoneal cavity they ~~align~~ ^{align} themselves along these surfaces ~~on one of their flat sides~~ ^{on one of their flat sides}, increasing the surface area of the device in contact with the vascular surface. This further increases the diffusion rate of oxygen and carbon dioxide as well as nutrients and glucose and insulin between the host and the microdisc resulting in increased efficiency as well as increased support of the ~~enclosed~~ ^{transplanted} endocrine cell. Even though the microdiscs ~~exist as a result of~~ ^{exist as a result of} ~~enclosed~~ ^{enclosed} ~~in a microcapsule~~ ^{in a microcapsule} ~~the~~ ^{the} ~~enclosed~~ ^{enclosed} ~~cell~~ ^{cell} ~~microdisc~~ ^{microdisc} achieves increased efficiency ^{intrinsically} on the basis of its favorable geometry with increased surface/volume ratio as well as its enhanced interaction with vascular body surfaces as a result of its increased contact area.

Additionally, when ~~transplanted~~ ^{transplanted} in smaller body cavities, the endocrine cell microdiscs can be stacked allowing more endocrine cells per unit area ~~than could be achieved with microspheres~~ ^{than could be achieved with microspheres}. This allows the transplantation of more endocrine cells at a given body site and may obviate the need for utilization of multiple sites and ~~complex~~ ^{complex} surgical procedures.

Rate of diffusion of a substance = $\frac{\text{Concentration difference of substance}}{\text{Distance of diffusion}}$ X (cross sectional surface area of the membrane X time)

such as the renal capsule

JUN 03 2005

OFFICE OF PETITIONS

In a preferred embodiment the ~~micro~~ endocrine cell microdisk is further enhanced by central dimpling of one or both of its flattened surfaces creating ~~an~~ an endocrine cell ~~biconcave microdisk~~. This uniconcave or biconcave microdisk further increases the surface/volume ratio of the device while preserving its sticking ability.

Comparing an endocrine cell microsphere with an endocrine cell biconcave microdisk of the same ~~total~~ total volume of 90 nm^3 , the surface area of the microsphere is 48 nm^2 , while the surface area of the concave microdisk is 140 nm^2 .

Detailed Description of the Invention

~~pancreatic islet cells are separated from the~~

Since the main application of this device is as an artificial endocrine pancreas for the treatment of Diabetes mellitus, an insulin producing islet cell microdisk or uniconcave or biconcave microdisk will be described.

Insulin producing islet cells (beta cells) are separated from the ~~pancreas~~ ^{exocrine pancreas} by collagenase digestion and purified by density gradient centrifugation as is well-known in the art. These cells are

combined ~~with~~ with various substances to produce ~~micro~~ microporous microspheres encapsulating them.

Some substances well-known in the micro-encapsulating art are alginate, ~~with various salts of~~ Barium alginate, alginate polyamine acid, alginate-polylysine-alginate, agarose, agarose-polyethylene, Hydrogels and polyanion complexes, and polymers such as hydroxyethylmethacrylate-methylmethacrylate (HEMA-MMA), and ANCA (Polyacrylonitrile).

Exhibit B



05/31/2005 14:59 FAX

004

Brief Description of The Invention.

Instead of the spherical shape of current microcapsules the endocrine cell containing microcapsules are generally flattened on two sides creating coin or pill shaped microcapsules or microdisks. This effectively increases the surface/volume ratio of the devices and increases the diffusional capacity per unit of time.

Moreover, when transplanted in a body cavity with large surfaces (vascular membranes) such as the peritoneal cavity they align themselves along these surfaces on one of their flat sides, increasing the surface area of the device in contact with the vascular surface and reducing the diffusion distance. This further increases the diffusion rate of oxygen and carbon dioxide as well as nutrients and glucose and insulin between the host and the microdisk resulting in increased efficiency as well as increased support of the enclosed transplanted endocrine cell.

RECEIVED**JUN 03 2005****OFFICE OF PETITIONS**